Stem cells have the power to regenerate tissues throughout the body
Experienced scientific management team with a past record of senior positions in the pharma industry, in companies such as Teva, Gamida Cell, Dexcel, Trima. Team members hold advanced degrees from top universities and research institutes in the US and in Israel.
Mr. Marom received his BSc in Chemical Engineering from the Technion – Israel Institute of Technology with distinction. He brings vast experience in management, operations, business and strategic planning in the pharmaceutical industry, where he has held various senior positions over the years. Past positions include VP of Operations at Teva Pharmaceuticals’ API and Innovative divisions, where he was credited for his contribution to the market success of Teva; COO of Peptor Ltd; CEO of the Jerusalem-based biotechnology company, Gamida Cell, a leader in hematopoietic (blood) stem cell therapeutics; President and CEO of Makhteshim Chemical Works Ltd., followed by position of Senior VP of Supply Chain at Makhteshim-Agan Group. In addition to his role as Chairman & CEO at Stem Cell Medicine, Mr. Marom also acts as Chairman & CEO of Mapi Pharma.
Ms. Zalayet CPA serves as Stem Cell Medicine’s CFO as of 2012. Prior to this Ms. Zalayet served as deputy CEO of Kesselman & Kesselman Trust Co. (1971) Ltd. and as a CPA at PwC Israel. Irit completed her Bachelors in Economics and Accounting and her M.A. in Law; both degrees are from The Bar-Ilan University. Ms. Zalayet also serves as the CFO of a related group party Pharma Two B.
Dr. Hayden Ideses holds a PhD in Organic Chemistry from the Ben Gurion University in Beer Sheva, Israel. Past experience includes Makhteshim Chemical Works R&D Department as Team Leader, Teva API Division as QC Manager 1991-1995, Dexcel Pharma R&D QA Manager 1995-2002, Trima Pharmaceutical Industry – Quality Assurance Manager 2002-2016
Ms. Saciuk joined Stem Cell Medicine in 2019. Previously, she worked at the aerospace engineering industry in Asia where she served as Business Development Manager and founded a representative office in China. She received her BA in Philosophy and East Asia Studies from the Hebrew University and received an MA in Political Science from National Taiwan University. She is fluent in Mandarin Chinese.
Uri Danon serves as our VP Clinical Development. Mr. Danon served as president and later as chief executive officer of BioCancell Therapeutics Inc. (TASE: BICL), a clinical stage anti-cancer drug development company. He also previously served as chief executive officer of Atox Bio Ltd., a clinical stage drug development company focused on the treatment of severe infections and served as the company’s chairman of the board of directors from 2009 until November 2013. He previously managed international projects for Teva Pharmaceutical Industries Ltd., from 1994 to 2000, and was chief executive officer of Epigenesis, Ltd., a cell therapy development company, from 2001 to 2003. Mr. Danon holds an MBA in marketing from Bar Ilan University, Israel, and a B.Sc. in industrial engineering and management from Tel Aviv University, Israel.
Shai Rubnov serves as our vice president of research and development. From 2007 to 2009, Dr. Rubnov served as head of chemistry, manufacturing and control, quality assurance and regulatory affairs at Therapix Bioscience Ltd. (formerly NasVax Ltd.), an Israeli drug development company. From 2002 to 2007, Dr. Rubnov served as a director of chemistry, manufacturing and control at DeveloGen AG., a German-Israeli biotechnology company, where he gained extensive experience in investigational new drug development and medicinal chemistry. Dr. Rubnov holds a PhD in medicinal chemistry and a BPharm from the Hebrew University in Jerusalem, Israel. Dr. Rubnov has completed his post-doctoral training at the French National Center for Scientific Research in Paris.
Dr. Yudin has extensive experience in the areas of neuro-cell and molecular biology, developing stem cell-based therapeutic methods for the treatment of multiple sclerosis, critical limb ischemia and other diseases. He served on the R&D team at Gamida Cell, in the area of development of hematological transplants based on expanded cord blood stem cells. Dr. Yudin holds a PhD in Biological Chemistry from the Weizmann Institute Of Science, Rehovot, and a post-doctoral degree from Columbia University, New-York
Mr. Gomberg has extensive experience in the areas of formulation of pharmaceutical preparations and clinical pharmacology and advanced nursing care. He served as R&D Project Manager at Dexcel Pharma, where he worked in developing formulations of tablets and semi-solids and participated in patent writing and submission of clinical trial batches for Phase I, Phase II, and clinical trials of Bioequivalence studies. Mr. Gomberg holds a B.Pharm degree from the Hebrew University of Jerusalem
Dr. Geffen has extensive experience in the areas of clinical and preclinical drug development. She served as CEO of Avraham Pharmaceuticals, a phase 2b clinical stage company developing drugs for Alzheimer’s disease, and VP R&D and Validation at Compugen Ltd (NASDAQ: CGEN). Dr. Geffen holds a Ph.D from the Department of Immunology and Microbiology and an M.Sc. in business management, both from the Ben-Gurion University, Israel.